Literature DB >> 9077606

Vertical transmission of toxoplasma by human immunodeficiency virus-infected women.

H Minkoff1, J S Remington, S Holman, R Ramirez, S Goodwin, S Landesman.   

Abstract

OBJECTIVE: Our goal was to determine the frequency of mother-to-child transmission of Toxoplasma gondii from human immunodeficiency virus-infected mothers who are also chronically infected with T. gondii. STUDY
DESIGN: One hundred thirty-eight women were entered into a prospective study of human immunodeficiency virus infection in pregnancy. The women were seen at enrollment, during the third, sixth, and eighth months of pregnancy (except those enrolled later in pregnancy or at delivery), at 2 and 6 months post partum, and at 6-month intervals thereafter through 4 years after delivery. Standardized interviews and physical examinations were performed, and blood was drawn at each visit. Toxoplasma serologic testing was performed on the sample drawn earliest in pregnancy; the Sabin-Feldman dye test for immunoglobulin G antibodies and enzyme-linked immunoassays for immunoglobulins M, A, and E were used. Univariate analysis for categoric variables was performed with chi2 and two-tailed Fisher exact tests, and for continuous variables the Student t test was used. Statistical Analysis System procedures were followed.
RESULTS: Twenty-eight of 138 (20.2%) women who had positive test results for human immunodeficiency virus had positive findings of the Sabin-Feldman dye test. Serologic status for T. gondii did not correlate with age, immune status, parity, or drug use. One of 27 children born to women who were seropositive for both human immunodeficiency virus and T. gondii (one child's serologic status for T. gondii was unknown) had Sabin-Feldman dye test antibodies beyond age 6 months (3.7%, 95% confidence interval 0.09% to 18.9%). Among the cohort of human immunodeficiency virus-infected mothers the rate of mother-to-child human immunodeficiency virus transmission did not vary with maternal Toxoplasma status. However, with sample sizes of 28 and 110, respectively, for the mothers who were T. gondii seropositive and seronegative, the power to detect a difference in the human immunodeficiency virus transmission rate between these groups would be relatively small.
CONCLUSIONS: Transmission of T. gondii from a chronically infected mother can occur in the setting of a human immunodeficiency virus infection, but this is not a common phenomenon. In a small cohort of human immunodeficiency virus-infected women we did not observe its occurrence among those without severe immunocompromise.

Entities:  

Mesh:

Year:  1997        PMID: 9077606     DOI: 10.1016/s0002-9378(97)70547-7

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  13 in total

Review 1.  Toxoplasmosis: A history of clinical observations.

Authors:  Louis M Weiss; Jitender P Dubey
Journal:  Int J Parasitol       Date:  2009-02-13       Impact factor: 3.981

2.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

3.  Prevalence and predictors of Toxoplasma seropositivity in women with and at risk for human immunodeficiency virus infection.

Authors:  Oluwatoyin Falusi; Audrey L French; Eric C Seaberg; Phyllis C Tien; D Heather Watts; Howard Minkoff; Eva Piessens; Andrea Kovacs; Kathryn Anastos; Mardge H Cohen
Journal:  Clin Infect Dis       Date:  2002-11-11       Impact factor: 9.079

4.  Toxoplasma gondii antibody profile in HIV-infected pregnant women and the risk of congenital toxoplasmosis.

Authors:  E G Lago; G S Conrado; C S Piccoli; R L Carvalho; A L Bender
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-10-15       Impact factor: 3.267

5.  Toxoplasmosis during pregnancy: a case report and review of the literature.

Authors:  C Giannoulis; B Zournatzi; A Giomisi; E Diza; I Tzafettas
Journal:  Hippokratia       Date:  2008-07       Impact factor: 0.471

6.  Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  Lynne M Mofenson; Michael T Brady; Susie P Danner; Kenneth L Dominguez; Rohan Hazra; Edward Handelsman; Peter Havens; Steve Nesheim; Jennifer S Read; Leslie Serchuck; Russell Van Dyke
Journal:  MMWR Recomm Rep       Date:  2009-09-04

7.  When pregnant women are not screened for HIV.

Authors:  Alon Shrim; Facundo Garcia-Bournissen; Kellie Murphy; Gideon Koren; Dan Farine
Journal:  Can Fam Physician       Date:  2007-10       Impact factor: 3.275

8.  Mother-to-child transmission of human immunodeficiency virus in aten years period.

Authors:  Adriane M Delicio; Helaine Milanez; Eliana Amaral; Sirlei S Morais; Giuliane J Lajos; João Luiz C Pinto e Silva; José Guilherme Cecatti
Journal:  Reprod Health       Date:  2011-11-30       Impact factor: 3.223

9.  Serological Responses to Toxoplasma gondii and Matrix Antigen 1 Predict the Risk of Subsequent Toxoplasmic Encephalitis in People Living With Human Immunodeficiency Virus (HIV).

Authors:  Jianchun Xiao; Fiona Bhondoekhan; Eric C Seaberg; Otto Yang; Valentina Stosor; Joseph B Margolick; Robert H Yolken; Raphael P Viscidi
Journal:  Clin Infect Dis       Date:  2021-10-05       Impact factor: 9.079

10.  Immunopathogenesis of toxoplasmosis in pregnancy.

Authors:  J Dupouy-Camet
Journal:  Infect Dis Obstet Gynecol       Date:  1997
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.